PecFent

Land: Europese Unie

Taal: Engels

Bron: EMA (European Medicines Agency)

Koop het nu

Bijsluiter Bijsluiter (PIL)
04-04-2024
Productkenmerken Productkenmerken (SPC)
04-04-2024

Werkstoffen:

fentanyl

Beschikbaar vanaf:

Kyowa Kirin Holdings B.V.

ATC-code:

N02AB03

INN (Algemene Internationale Benaming):

fentanyl

Therapeutische categorie:

Analgesics

Therapeutisch gebied:

Pain; Cancer

therapeutische indicaties:

PecFent is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equi-analgesic dose of another opioid for a week or longer.

Product samenvatting:

Revision: 23

Autorisatie-status:

Authorised

Autorisatie datum:

2010-08-31

Bijsluiter

                                38
B. PACKAGE LEAFLET
39
PACKAGE LEAFLET: INFORMATION FOR THE USER
PECFENT 100 MICROGRAMS/SPRAY NASAL SPRAY, SOLUTION
PECFENT 400 MICROGRAMS/SPRAY NASAL SPRAY, SOLUTION
fentanyl
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctoror pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What PecFent is and what it is used for
2.
What you need to know before you use PecFent
3.
How to use PecFent
4.
Possible side effects
5.
How to store PecFent
6.
Contents of the pack and other information
1.
WHAT PECFENT IS AND WHAT IT IS USED FOR
WHAT PECFENT IS
PecFent contains fentanyl, which is a strong pain-relieving medicine
known as an opioid pain killer.
WHAT PECFENT IS USED FOR
PecFent is used in adults with cancer for a type of pain called
‘breakthrough’ pain.
•
Breakthrough pain comes on suddenly.
•
It comes on even though you have taken your usual opioid pain killer
(such as morphine,
fentanyl, oxycodone or hydromorphone) to control your constant
background pain.
PecFent is only to be used by adults who are already taking other
opioid medicines daily for their
constant cancer pain.
HOW PECFENT WORKS
PecFent is a nasal spray, solution
•
When you spray PecFent into your nose the very small spray droplets
form a thin gel.
•
Fentanyl is absorbed quickly through the lining of your nose and into
the blood stream.
•
This means the medicine gets into your system quickly to relieve your
breakthrough pain.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE PECFENT
DO NOT USE PECFENT IF:
•
you are allergic to fentanyl or any of the other ingredients of this
medicine (
                                
                                Lees het volledige document
                                
                            

Productkenmerken

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
PecFent 100 micrograms/spray nasal spray, solution
PecFent 400 micrograms/spray nasal spray, solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
PecFent 100 micrograms/spray nasal spray, solution
Each ml of solution contains 1,000 micrograms fentanyl (as citrate)
1 spray (100 microlitres) contains 100 micrograms fentanyl (as
citrate)
Bottles contain:
0.95 ml (950 micrograms fentanyl) -
2 spray bottle
or
1.55 ml (1,550 micrograms fentanyl) - 8 spray bottle
PecFent 400 micrograms/spray nasal spray, solution
Each ml of solution contains 4,000 micrograms fentanyl (as citrate)
1 spray (100 microlitres) contains 400 micrograms fentanyl (as
citrate)
Each bottle contains 1.55 ml (6,200 micrograms fentanyl)
Excipients with known effect:
_ _
Each spray contains 0.02 mg propylparahydroxybenzoate (E216).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Nasal spray, solution (nasal spray).
A clear to practically clear colourless aqueous solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
PecFent is indicated for the management of breakthrough pain (BTP) in
adults who are already
receiving maintenance opioid therapy for chronic cancer pain.
Breakthrough pain is a transitory
exacerbation of pain that occurs on a background of otherwise
controlled persistent pain.
Patients receiving maintenance opioid therapy are those who are taking
at least 60 mg of oral
morphine daily, at least 25 micrograms of transdermal fentanyl per
hour, at least 30 mg of oxycodone
daily, at least 8 mg of oral hydromorphone daily or an equianalgesic
dose of another opioid for a week
or longer.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment should be initiated by and remain under the supervision of a
physician experienced in the
management of opioid therapy in cancer patients. Physicians should
keep in mind the potential for
abuse of fentanyl.
3
Posology
PecFent should be titrated to an “effective” dose that provides
adequate anal
                                
                                Lees het volledige document
                                
                            

Documenten in andere talen

Bijsluiter Bijsluiter Bulgaars 04-04-2024
Productkenmerken Productkenmerken Bulgaars 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Bulgaars 03-08-2018
Bijsluiter Bijsluiter Spaans 04-04-2024
Productkenmerken Productkenmerken Spaans 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Spaans 03-08-2018
Bijsluiter Bijsluiter Tsjechisch 04-04-2024
Productkenmerken Productkenmerken Tsjechisch 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Tsjechisch 03-08-2018
Bijsluiter Bijsluiter Deens 04-04-2024
Productkenmerken Productkenmerken Deens 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Deens 03-08-2018
Bijsluiter Bijsluiter Duits 04-04-2024
Productkenmerken Productkenmerken Duits 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Duits 03-08-2018
Bijsluiter Bijsluiter Estlands 04-04-2024
Productkenmerken Productkenmerken Estlands 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Estlands 03-08-2018
Bijsluiter Bijsluiter Grieks 04-04-2024
Productkenmerken Productkenmerken Grieks 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Grieks 03-08-2018
Bijsluiter Bijsluiter Frans 04-04-2024
Productkenmerken Productkenmerken Frans 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Frans 03-08-2018
Bijsluiter Bijsluiter Italiaans 04-04-2024
Productkenmerken Productkenmerken Italiaans 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Italiaans 03-08-2018
Bijsluiter Bijsluiter Letlands 04-04-2024
Productkenmerken Productkenmerken Letlands 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Letlands 03-08-2018
Bijsluiter Bijsluiter Litouws 04-04-2024
Productkenmerken Productkenmerken Litouws 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Litouws 03-08-2018
Bijsluiter Bijsluiter Hongaars 04-04-2024
Productkenmerken Productkenmerken Hongaars 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Hongaars 03-08-2018
Bijsluiter Bijsluiter Maltees 04-04-2024
Productkenmerken Productkenmerken Maltees 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Maltees 03-08-2018
Bijsluiter Bijsluiter Nederlands 04-04-2024
Productkenmerken Productkenmerken Nederlands 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Nederlands 03-08-2018
Bijsluiter Bijsluiter Pools 04-04-2024
Productkenmerken Productkenmerken Pools 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Pools 03-08-2018
Bijsluiter Bijsluiter Portugees 04-04-2024
Productkenmerken Productkenmerken Portugees 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Portugees 03-08-2018
Bijsluiter Bijsluiter Roemeens 04-04-2024
Productkenmerken Productkenmerken Roemeens 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Roemeens 03-08-2018
Bijsluiter Bijsluiter Slowaaks 04-04-2024
Productkenmerken Productkenmerken Slowaaks 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Slowaaks 03-08-2018
Bijsluiter Bijsluiter Sloveens 04-04-2024
Productkenmerken Productkenmerken Sloveens 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Sloveens 03-08-2018
Bijsluiter Bijsluiter Fins 04-04-2024
Productkenmerken Productkenmerken Fins 04-04-2024
Bijsluiter Bijsluiter Zweeds 04-04-2024
Productkenmerken Productkenmerken Zweeds 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Zweeds 03-08-2018
Bijsluiter Bijsluiter Noors 04-04-2024
Productkenmerken Productkenmerken Noors 04-04-2024
Bijsluiter Bijsluiter IJslands 04-04-2024
Productkenmerken Productkenmerken IJslands 04-04-2024
Bijsluiter Bijsluiter Kroatisch 04-04-2024
Productkenmerken Productkenmerken Kroatisch 04-04-2024
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Kroatisch 03-08-2018

Zoekwaarschuwingen met betrekking tot dit product

Bekijk de geschiedenis van documenten